Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Mei Zhang
- Target Recruit Count
- 112
- Registration Number
- NCT05636644
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfo Mountain Hospital), Jinan, Shandong, China
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT05636111
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 400
- Registration Number
- NCT05635708
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇰🇷Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do, Korea, Republic of
Study of Novel Treatment Combinations in Patients With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 593
- Registration Number
- NCT05633667
- Locations
- 🇧🇷
Hospital Mae de Deus, Porto Alegre, Brazil
🇧🇷Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil
🇬🇧Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05628610
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
- Conditions
- Interventions
- Drug: CarboplatinDrug: CisplatinProcedure: Computed TomographyBiological: DurvalumabDrug: EtoposideRadiation: Image Guided Radiation TherapyDrug: PaclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT05624996
- Locations
- 🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
🇺🇸Benefis Sletten Cancer Institute, Great Falls, Montana, United States
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 90
- Registration Number
- NCT05613088
- Locations
- 🇦🇺
Local Institution - 0016, Sydney, New South Wales, Australia
🇦🇺Local Institution - 0017, Waratah, New South Wales, Australia
🇦🇺Local Institution - 0015, Clayton, Victoria, Australia
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT05605535
- Locations
- 🇮🇳
King George Hospital, Visakhapatnam, Andhra Pradesh, India
🇮🇳Omega Hospitals, Visakhapatnam, Andhra Pradesh, India
🇮🇳Kailash Cancer Hospital and Research Centre, Vadodara, Gujarat, India
Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Moscow Clinical Scientific Center
- Target Recruit Count
- 35
- Registration Number
- NCT05580887
- Locations
- 🇷🇺
Moscow Clinical Scientific Center named after AS Loginov, Moscow, Not Required, Russian Federation
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 121
- Registration Number
- NCT05577702
- Locations
- 🇨🇳
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.